Calcium Channel Dysfunction in Neurodegeneration

Calcium Channel Dysfunction in Neurodegeneration

Introduction

Calcium Channel Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Calcium (Ca²⁺) signaling is fundamental to neuronal function, controlling neurotransmitter release, gene transcription, synaptic plasticity, and cellular survival. Dysregulation of calcium homeostasis is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular mechanisms of calcium channel dysfunction and its contribution to neurodegeneration. [@surmeier2017]

Overview

[Neurons](/entities/neurons) maintain precise control over intracellular calcium concentrations through a sophisticated network of channels, pumps, buffers, and transporters. Disruption of this equilibrium leads to: [@khachaturian1994]

• [Excitotoxicity](/mechanisms/excitotoxicity)
• Mitochondrial dysfunction
• Oxidative stress
• Activation of apoptotic pathways
• Synaptic failure

Calcium Channel Dysfunction in Neurodegeneration

Introduction

Calcium Channel Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Calcium (Ca²⁺) signaling is fundamental to neuronal function, controlling neurotransmitter release, gene transcription, synaptic plasticity, and cellular survival. Dysregulation of calcium homeostasis is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular mechanisms of calcium channel dysfunction and its contribution to neurodegeneration. [@surmeier2017]

Overview

[Neurons](/entities/neurons) maintain precise control over intracellular calcium concentrations through a sophisticated network of channels, pumps, buffers, and transporters. Disruption of this equilibrium leads to: [@khachaturian1994]

• [Excitotoxicity](/mechanisms/excitotoxicity)
• Mitochondrial dysfunction
• Oxidative stress
• Activation of apoptotic pathways
• Synaptic failure

Voltage-Gated Calcium Channel Types

High-Voltage Activated (HVA) Channels

| Channel Type | Gene | Primary Location | Function | [@stutzmann2007]
|--------------|------|------------------|----------| [@mattson2004]
| L-type (CaV1.x) | CACNA1A-D | Dendrites, cell body | Gene transcription, plasticity | [@popugaeva2018]
| N-type (CaV2.2) | CACNA1B | Presynaptic terminals | Neurotransmitter release | [@chan2009]
| P/Q-type (CaV2.1) | CACNA1A | Presynaptic terminals | neurotransmitter release | [@giacomello2005]
| R-type (CaV2.3) | CACNA1E | Dendrites, terminals | Residual Ca²⁺ influx | [@demuro2006]

Low-Voltage Activated (LVA) Channels

| Channel Type | Gene | Primary Location | Function | [@berridge2011]
|--------------|------|------------------|----------| [@palop2014]
| T-type (CaV3.x) | CACNA1G-I | Thalamic neurons | Pacemaking, burst firing | [@zndorf2011]

Calcium Dysregulation in Alzheimer's Disease

Store-Operated Calcium Entry (SOCE)

In AD, the endoplasmic reticulum (ER) calcium store becomes depleted due to: [@marongiu2009]

• Ryanodine Receptor (RyR) leak: Elevated RyR3 expression leads to ER Ca²⁺ leak
• IP₃ receptor dysfunction: Altered IP₃ signaling disrupts store release
• SERCA pump impairment: Reduced SERCA activity diminishes Ca²⁺ reuptake

NMDA Receptor Dysfunction

• NR2B-containing NMDA receptors show increased activity in AD
• Extrasynaptic NMDA receptors promote Ca²⁺ overload
• Altered NMDA subunit composition (NR2A/NR2B ratio) affects signaling

L-Type Channel Alterations

• CaV1.2 channels show increased expression in AD neurons
• Enhanced L-type currents contribute to dendritic Ca²⁺ dysregulation
• Mode shifting observed in AD states

Calcium Dysregulation in Parkinson's Disease

Pacemaker Dysfunction

Dopaminergic neurons in the substantia nigra pars compacta (SNc) rely on L-type Ca²⁺ channels (CaV1.3) for autonomous pacemaking. This creates: [@wang2023]

• Constant Ca²⁺ influx during action potentials
• Enhanced mitochondrial oxidative stress
• Accelerated aging of dopaminergic neurons

Cav1.3 Channel Properties

• Activates at more negative voltages than CaV1.2
• Contributes substantially to the "slow pacemaker" current
• Risk factor for selective vulnerability of SNc neurons

Mitochondrial Calcium Overload

• Ca²⁺ accumulation in mitochondria
• Enhanced [ROS](/entities/reactive-oxygen-species) production
• Activation of mitochondrial permeability transition
• Triggering of apoptotic pathways

Therapeutic Targeting

Calcium Channel Blockers

| Drug/Compound | Target | Clinical Status | Notes |
|---------------|--------|-----------------|-------|
| Isradipine | CaV1.2 | Phase 2/3 (AD) | Failed to meet primary endpoints |
| Nilvadipine | CaV1.2 | Phase 3 (AD) | Mixed results |
| Flunarizine | CaV2.2 | Approved (migraine) | Potential neuroprotective effects |
| Ziconotide | CaV2.1 | Approved (pain) | Too toxic for chronic use |

Mode Gating Modulators

• CGP-37157: Mitochondrial Na⁺/Ca²⁺ exchange blocker
• RS-10046: RyR stabilizer in preclinical studies

SOCE Inhibitors

• DPB162-AE: STIM1 inhibitor (preclinical)
• ML-9: STIM1/Orai1 inhibitor (preclinical)

Molecular Components Table

| Component | Gene | Function | Disease Relevance |
|-----------|------|----------|-------------------|
| CaV1.2 | CACNA1C | L-type, dendritic Ca²⁺ | AD risk gene |
| CaV1.3 | CACNA1D | L-type, pacemaking | PD vulnerability |
| CaV2.2 | CACNA1B | N-type, presynaptic | Therapeutic target |
| CaV2.1 | CACNA1A | P/Q-type, release | Ataxia, migraine |
| CaV3.1 | CACNA1G | T-type, thalamic | Epilepsy, AD |
| STIM1 | STIM1 | SOCE sensor | ER Ca²⁺ store depletion |
| ORAI1 | ORAI1 | SOCE channel | Store-operated influx |
| RyR1-3 | RYR1-3 | ER Ca²⁺ release | AD increased leak |
| SERCA2 | ATP2A2 | ER Ca²⁺ reuptake | AD decreased activity |
| NCX | SLC8A1-3 | Mitochondrial Ca²⁺ | Mitochondrial dysfunction |

Disease-Specific Mechanisms

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral sclerosis

Research Highlights

Key Publications

Emerging Concepts

• Neuroprotective strategies focusing on L-type blockers
• Mitochondrial calcium uniporter (MCU) targeting
• ER stress mitigation as therapeutic approach
• Gene therapy for Ca²⁺ channel modulation

Cross-Links

• [Calcium Dysregulation in AD](/mechanisms/calcium-dysregulation-ad)
• [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
• [Neuronal Hyperexcitability](/mechanisms/neuronal-hyperexcitability)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-pathway)

External Links

• [PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
• [Allen Brain Atlas](https://brain-map.org/)
• [BrainSpan Atlas](https://brainspan.org/)

See Also

• [Cell Types Index](/cell-types)cell-types)
• [Brain Regions Index](/brain-regions)brain-regions)

Background

The study of Calcium Channel Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

• Ultrasonic repression of TRPA1-dependent astrocyte reactivity confers neuroprotection in models of Lewy body dementia. (Transl Neurodegener, 2026). PMID: 41808144(https://pubmed.ncbi.nlm.nih.gov/41808144/)
• Class-Specific Antihypertensives and Alzheimer's Disease: Genotype- and Hypertension-Stratified Analysis. (Mol Neurobiol, 2026). PMID: 41806233(https://pubmed.ncbi.nlm.nih.gov/41806233/)
• Pro-tumoral Ca(2+) signaling is dependent on Slowpoke and Ca-α1T channels in Drosophila melanogaster glioma. (Sci Rep, 2026). PMID: 41792312(https://pubmed.ncbi.nlm.nih.gov/41792312/)
• Selective Ca(v)1.3 inhibition promotes survival of transplanted dopaminergic neurons via the CaMKII-p65-p53 pathway. (Stem Cell Reports, 2026). PMID: 41791389(https://pubmed.ncbi.nlm.nih.gov/41791389/)
• Calcium Signaling and Pathogenesis of Neurodegenerative Disorders: Potential Therapeutic Opportunities. (Cold Spring Harb Perspect Biol, 2026). PMID: 41786476(https://pubmed.ncbi.nlm.nih.gov/41786476/)

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |

Overall Confidence: 43%

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Calcium Channel Dysfunction in Neurodegeneration discovered through SciDEX knowledge graph analysis: